Skip to main content Back to Top


Reteplase Injection

Reason for the Shortage

    • Chiesi USA acquired Cornerstone Therapeutics in March 2014.
    • Cornerstone Therapeutics acquired EKR Therapeutics in June 2012. EKR Therapeutics had previously purchased Retavase from PDL BioPharma.
    • Cornerstone Therapeutics was seeking FDA approval of a new supplier of the active pharmaceutical ingredient for Retevase:

Available Products

    • Retavase injection, Chiesi, Full Kit, two 10 unit, single dose vial, NDC 10122-0141-02
    • Retavase injection, Chiesi, Half Kit, one 10 unit, single dose vial, NDC 10122-0143-01


Updated June 11, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. Created October 9, 2009 by Jane Chandramouli, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.


Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.